Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wedbush Downgrades Pegasystems to Neutral

Wedbush Downgrades Pegasystems to Neutral

Wedbush analyst Daniel Ives downgrades Pegasystems (NASDAQ:PEGA) from Outperform to Neutral.

byBenzinga Newsdesk

July 28, 2022

1 minute read

Wedbush analyst Daniel Ives downgrades Pegasystems (NASDAQ:PEGA) from Outperform to Neutral.

IBM’s Portfolio Makeover – Divests Weather Company Assets To Francisco Partners

By Nabaparna Bhattacharya

August 23, 10:10 AM

International Business Machines Corporation (NYSE: IBM) inked a pact on Tuesday to

IBM

Analyst Ratings

Critical Insights From Geron Analyst Ratings: What You Need To Know

By Benzinga Insights

June 10, 9:00 AM

Analysts’ ratings for Geron (NASDAQ:GERN) over the last quarter vary from bullish to bearish, as provided by 12…

GERN

RBC Capital Initiates Coverage On Penumbra with Outperform Rating, Announces Price Target of $195

By Benzinga Newsdesk

July 18, 7:36 AM

RBC Capital analyst Shagun Singh initiates coverage on Penumbra (NYSE:PEN) with a Outperform rating and announces Price Target of $195.

PEN

Medtronic’s PulseSelect PFA System Gets FDA Nod, Revolutionizing Atrial Fibrillation Treatment in US

By Vandana Singh

December 14, 8:39 AM

The FDA approved Medtronic plc's (NYSE: MDT) PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF), an irregular and often

MDT

Wedbush Downgrades Pegasystems to Neutral

Related Posts

IBM’s Portfolio Makeover – Divests Weather Company Assets To Francisco Partners

Critical Insights From Geron Analyst Ratings: What You Need To Know

RBC Capital Initiates Coverage On Penumbra with Outperform Rating, Announces Price Target of $195

Medtronic’s PulseSelect PFA System Gets FDA Nod, Revolutionizing Atrial Fibrillation Treatment in US